Long‑COVID in children and adolescents: a systematic review and meta‑analyses Sandra Lopez‑Leon 1,2, Talia Wegman‑Ostrosky 3, Norma Cipatli Ayuzo del Valle 4, Carol Perelman 5, Rosalinda Sepulveda 6, Paulina A. Rebolledo 7,8, Angelica Cuapio Sonia Villapol 10,11* 9 & The objective of this systematic review and meta-analyses is to estimate the prevalence of longCOVID in children and adolescents and to present the full spectrum of symptoms present after acute COVID-19. We have used PubMed and Embase to identify observational studies published before February 10th, 2022 that included a minimum of 30 patients with ages ranging from 0 to 18 years that met the National Institute for Healthcare Excellence (NICE) definition of long-COVID, which consists of both ongoing (4 to 12 weeks) and post-COVID-19 (≥ 12 weeks) symptoms. Randomeffects meta-analyses were performed using the MetaXL software to estimate the pooled prevalence with a 95% confidence interval (CI). Heterogeneity was assessed using ­I2 statistics. The Preferred Reporting Items for Systematic Reviewers and Meta-analysis (PRISMA) reporting guideline was followed (registration PROSPERO CRD42021275408). The literature search yielded 8373 publications, of which 21 studies met the inclusion criteria, and a total of 80,071 children and adolescents were included. The prevalence of long-COVID was 25.24%, and the most prevalent clinical manifestations were mood symptoms (16.50%), fatigue (9.66%), and sleep disorders (8.42%). Children infected by SARS-CoV-2 had a higher risk of persistent dyspnea, anosmia/ageusia, and/or fever compared to controls. Limitations of the studies analyzed include lack of standardized definitions, recall, selection, misclassification, nonresponse and/or loss of follow-up, and a high level of heterogeneity. Abbreviations CI Confidence interval COVID-19 Coronavirus disease 2019 CSS Cross-sectional study DM Diabetes mellitus QCed Quality-controlled IRR Incidence rate ratios NICE National Institute for Health and Care Excellence MIS-C Multisystem inflammatory syndrome ORs Odds ratios PCS Prospective cohort study PRISMA Preferred Items for Systematic Reviews and Meta-analyses RCS Retrospective cohort study rt-PCR Real-time reverse transcription-polymerase chain reaction 1 Quantitative Safety & Epidemiology, Novartis Pharmaceuticals, East Hanover, NJ, USA. 2Rutgers Center for Pharmacoepidemiology and Treatment Science, Rutgers University, New Brunswick, NJ, USA. 3Subdirección de Investigación básica, Instituto Nacional de Cancerología, Mexico, Mexico. 4Departamento de Pediatría, Tecnologico de Monterrey, Monterrey, Mexico. 5Universidad Nacional Autónoma de México (UNAM), SOMEDICyT, RedMPC, Mexico City, Mexico. 6Harvard T.H. Chan School of Public Health, Boston, MA, USA. 7Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA. 8Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA. 9Department of Medicine Huddinge, Center for Infectious Medicine, Karolinska Institute, Stockholm, Sweden. 10Department of Neurosurgery, Center for Neuroregeneration, Houston Methodist Research Institute, 6670 Bertner Avenue, R10‑117, Houston, TX 77030, USA. 11Department of Neuroscience in Neurological Surgery, Weill Cornell Medical College, New York, USA. *email: svillapol@houstonmethodist.org Scientific Reports | (2022) 12:9950 | https://doi.org/10.1038/s41598-022-13495-5 1 Vol.:(0123456789) www.nature.com/scientificreports/ SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 PASC Post-acute sequelae of SARS-CoV-2 It has been over 2 years since the coronavirus disease 2019 (COVID-19) pandemic was first declared. Consequently, millions of cases and thousands of deaths have been reported w ­ orldwide1. Still, treatments have been developed during this time, and effective vaccines have been widely administered to the population, both children and adults, protecting millions from severe disease and d ­ eath2. Until now, the focus was primarily aimed at the acute phase of the disease. However, many individuals experience debilitating COVID-19 symptoms months later, requiring additional medical attention and follow-up. Severe COVID-19 is less common in children than in ­adults3; however, at least two long-term consequences occur following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in children: multisystem inflammatory syndrome (MIS-C) and long-COVID. Both consequences can even appear in asymptomatic ­patients4. MIS-C is a condition where different body parts become i­nflamed4, it occurs in less than 0.01% of children infected and requires intensive care support in 68% of c­ ases5. Long-COVID is a heterogeneous multisystemic condition for which there is still no precise definition and includes signs and symptoms that persist, develop, or fluctuate after SARS-CoV-2 infection. In October 2021, the WHO proposed a clinical definition for post-COVID-19 through a Delphi consensus stating it generally occurs three months from the onset of COVID-19, with symptoms lasting at least two months and cannot be explained by an alternative d ­ iagnosis6. On February 2nd, 2022, the National Institute for Health and Care Excellence (NICE) published a guideline defining long-COVID as signs and symptoms that continue or develop after acute COVID‑19. This includes ongoing symptomatic COVID-19 (from 4 to 12 weeks) and post‑COVID-19 syndrome (12 weeks or more)7. Other organizations, such as the National Institutes of Health (N.I.H.), also define long-COVID as post-acute symptoms after 4 ­weeks8. Many authors have used the following terms interchangeably when referring to longCOVID: long-haulers, COVID-long, post-acute sequelae of COVID-19 (PASC), post-COVID, COVID syndrome, and long-COVID. In the present study, we will use the generic definition from NICE and N.I.H., referring to long-COVID. To date, most of the published research on long-COVID primarily focuses on adult populations, and there is limited information on pediatric ­populations9,10. The most recent meta-analysis has studied the long-COVID symptoms and their prevalence, risk factors, type, and duration, including studies up to July 2021, encompassing 23,141 children and young p ­ eople9. The most common symptoms were fatigue 47%, dyspnea 43%, and headache 35%. In addition, compared to controls, the prevalence of cognitive difficulties, headache, loss of smell, sore throat, and sore eyes was statistically h ­ igher9. However, due to the lack of data, this study could only compute the pooled prevalence for 10 symptoms. To date, the potential range of signs and symptoms and their frequency of occurrence in children and adolescents remains ­unclear11. There is a need to create awareness among parents, physicians, and researchers on the afflictions following COVID-19 infection and the health system to better understand the sequelae to provide targeted medical attention and treatment. This systematic review and meta-analyses aim to estimate the prevalence of long-COVID in children and adolescents and identify the full spectrum of symptoms. Methods Data sources and search strategy. This systematic review and meta-analyses were reported following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting g­ uideline12. It examines the prevalence of long-COVID signs and symptoms in children under the age of 18 with a diagnosed case of COVID-19 (confirmed via real-time reverse transcription-polymerase chain reaction (rt-PCR), antigen or antibody (or serology tests). To achieve this, two independent investigators (T.W.O. and S.L.L.) searched PubMed and Embase to identify studies that met the following criteria: (1) a minimum of 30 patients, (2) ages ranged from 0 to 18 years, (3) studies published in English, (4) published before February 10th, 2022, and (5) meet the NICE definition of long-COVID, (6) excluding cohorts of children composed of exclusively pre-existing chronic diseases, or exclusively of MIS-C in children, and (7) excluding references of editorials, reviews, and commentaries (Fig. 1). The search terms used to identify publications discussing long-COVID in children were: (COVID-19 OR COVID OR SARSCOV-2 OR coronavirus OR “long-COVID” OR “post COVID”) AND (PASC OR haulers OR lingering OR “post-acute” OR persistent OR convalescent OR convalescence OR sequelae OR post-viral) AND (pediatric OR kids OR young OR infant OR children OR adolescents). Given that MedLine was included in the PubMed search, we excluded articles from MedLine in the Embase search along with those not related to COVID-19. Observational studies, including cohorts and cross-sectional studies, were analyzed only when the cases (numerator) were part of a COVID-19 cohort (denominator). Titles, abstracts, and full texts of articles were independently screened. Disagreement on including a full-text article was discussed among all the authors. We developed and registered a review protocol (PROSPERO registration number: CRD42021275408). Screening and data extraction. Data were extracted by four authors (A.C., N.C.A., P.R., R.S.) and Quality-Controlled (QCed) data by two authors (T.W.O., N.C.P.). Discrepancies were discussed with a third author. The descriptive variables extracted were country, study design, period of study, collection mode, follow-up time, the severity of COVID-19, sample size, COVID-19 diagnosis, age, percentage of males, outcomes, and names used to describe the long-term effects of COVID-19. Statistical analysis. Random-effects meta-analyses were performed for symptoms reported in two or more studies using MetaXL software to estimate the pooled prevalence, which uses a double arcsine t­ ransformation13. Scientific Reports | Vol:.(1234567890) (2022) 12:9950 | https://doi.org/10.1038/s41598-022-13495-5 2 www.nature.com/scientificreports/ Figure 1.  PRISMA diagram with exclusion criteria. Preferred Items for Systematic Reviews and Meta-Analyses (PRISMA) screening process flow. Out of 8373 identified studies and after applying the inclusion and exclusion criteria, 21 studies were included in the quantitative synthesis. Prevalence (presented as percentages) with 95% confidence intervals (C.I.s) was estimated. Numerators represented the number of children with long-COVID, and denominators described the total number of children with acute COVID-19 (with and without long-term effects). To compare cases and controls adjusted for confounders, we used Review Manager (RevMan) software 5.4 to estimate the odds ratios (O.R.s)14. A p-value < 0.05 was considered statistically significant. Given the heterogeneity expected, a random-effects model was employed using the ­I2 statistics. Values of 25, 50, and 75% for ­I2 represented low, medium, and high heterogeneity, respectively. Studies with high precision plotted near the average, and those with low precision are speeded evenly on both sides of the average. Deviation from a funnel shape distribution this shape can indicate publication ­bias14. The quality control of the study was assessed using the QCed data. The MetaXL Guidelines describe and recommend this index, which evaluates the quality of studies assessing prevalence. Results General characteristics of studies. The title and abstract of 8373 publications were screened. After duplicates were removed, the search identified 68 publications after screening titles and abstracts, and 47 were excluded because they did not fulfill the inclusion criteria. A total of 21 studies were selected for the analyses (Fig. 1). The general study characteristics are shown in Table 1. Different authors have used the terms “Post-acute COVID”, “long-COVID”, “Persistent COVID”, and “Persistent COVID Symptoms” as synonyms. Most of the studies assessed pre-specified symptoms included in a questionnaire. 18 of the selected studies come from European cohorts (Denmark, Russia, Italy, Germany, Tukey, Latvia, UK, France, Sweden, and Switzerland), one from Iran, one from Brazil, and one from Australia. The studies by K ­ ikkenborg15 and B ­ orch16 included an overlapping population (Denmark), as did ­Roge17 and ­Smane18 (Latvia). To ensure that no overlapping data were included, only the study with the largest sample size was included to estimate long-COVID and for outcomes reported in both studies. Still, several outcomes were only presented in one of the studies, therefore both studies were included in the overall meta-analysis. Four studies included only hospitalized patients, and the rest included all COVID-19 severities (asymptomatic, mild, moderate, and severe). The number of patients included in the studies ranged from 53 to 57,763, and ages ranged from 0 to 18 years. A total of 80,071 children and adolescents with COVID-19 were included in the meta-analyses. We identified more than 40 long-term clinical manifestations associated with COVID-19 in the literature reviewed (Table 2). Meta‑analyses of the prevalence of long‑COVID. The prevalence of long-COVID in children and adolescents, as defined by the presence of one or more symptoms more than 4 weeks following a SARS-CoV-2 infection, was 25.24% (95% CI 18.17–33.02, I­ 2 99.61%) (Figs. 2, 3). For hospitalized patients, the prevalence of long-COVID was 29.19% (95% CI 17.83–41.98, I­2 80.84%). The most common symptoms and percentage of prevalence associated were mood symptoms (e.g., sadness, tension, anger, depression, and anxiety) (16.50%; 95% CI 7.37–28.15, I­ 2 97.49%), fatigue (9.66%; 95% CI 4.45–16.46, ­I2 99.12%), sleep disorders (e.g., insomnia, hypersomnia, and poor sleep quality) (8.42%; 95% CI 3.41–15.20, I­ 2 93.49%); headache (7.84%; 95% CI 4.04– 12.70, ­I2 98.49%), respiratory symptoms (7.62%; 95% CI 2.08–15.78, I­2 99.15%), sputum production or nasal Scientific Reports | (2022) 12:9950 | https://doi.org/10.1038/s41598-022-13495-5 3 Vol.:(0123456789) www.nature.com/scientificreports/ Author Country Study design Follow-up time Collection included in M.A. mode Severity% N cases (denominator) COVID19 N controls diagnoses Control definition Age range Sex% Male Term Asadi‑Pooya19 Iran CSS Phone (questionnaire) Blankenburg20 Germany CSS Schools (survey) > 3 months NR 188 1365 IgG IgG negative 14 to 16 45 LongCOVID19 Borch16 Denmark RCS Electronic (questionnaire) > 1 month Asymptomatic 15,041 15,080 PCR Not a PCR positive in the past 0 to 17 NR Long COVID Buonsenso21 Italy CSS Phone or inpatient (questionnaire) > 4 months All severities 129 NA PCR NA > 18 52 Long COVID 95* “Tested positive” Not having contact with some> 18 one with COVID19.19 54 Long COVID Negative PCR or antibody* 8 to 18 42 PostCOVID-19/ long term PASC/long COVID-19 Erol22 Turkey > 3 months Hospitalized 58 NA PCR NA 6 to 17 48 Long COVID RCS Clinical 5.6 months average All severities 4.4 months average Symptomatic 53 (Outpatient and inpatients) 52* PCR or antibody 2 months All severities 6630 21,640 Tested positive Not tested positive 15 to 18 58 Long COVID Asymptomatic 73 45 PCR or antibody No antibodies, 5 to 18 31% other infection 48 Long term COVID/ persistent symptoms 121 Fink23 Brazil PCS Outpatient and inpatients validated instruments and clinic Kikkenborg Berg*15 Denmark CSS Electronic (survey) CSS Outpatient (question2.6 months naire and pulmonary average function testing) 10 to 13 months All severities 137 NA PCR NA 0 to 15 NR Long-term consequences/ persisting symptoms/ long COVID Knoke24 Germany Matteudi25 France PCS Phone (questionnaire) Miller26 U.K. PCS Electronic (weekly survey) ≥ 1 month NR 174 NA “Nasal swab” NA ≤ 17 45 Persistent symptoms/ long COVID Molteni27 U.K. PCS Electronic App > 2 months NR 1734 NA PCR IgG NA 5 to 17 50 Persistent symptoms Hospitalized 518 NA PCR NA 3 to 15 47 Long term/ long covid/ persistent symtoms Asymptomatic and mild 109 1246 Serology Seronegative 6 to 16 46 Long COVID/ SARS-Cov-2 postviral syndromes 55.50 Persistent symptoms/long COVID/ long-term consequences/ long-lasting symptoms/ long-term persistent symptoms/ late sequelae of COVID19 Osmanov28 Russia PCS Phone (SARIC COVID-19 Health and > 5 months Wellbeing Follow-Up Survey for Children) Radtke29 Switzerland PCS Online (questionnaire) Roge17 Latvia PCS and RCS Phone (questionnaire) > 3 months 1 to 6 months All severities 236 142 PCR or seroconversion Other infections 0 to 18 Continued Scientific Reports | Vol:.(1234567890) (2022) 12:9950 | https://doi.org/10.1038/s41598-022-13495-5 4 www.nature.com/scientificreports/ Author Country Study design Follow-up time Collection included in M.A. mode Severity% N cases (denominator) COVID19 N controls diagnoses Control definition Age range Sex% Male Term Roessler30 Germany RCS Health Insurance data ≥ 3 months All severities 57,763 288,815* Laboratory virus detection Nonlaboratory virus detection 0 to 17 51.30 Post COVID19/ long term health sequelae/ post-acute COVID-19 syndrome/ post COVID-19 condition Rusetsky31 Russia PCS Phone At 2 months Hospitalized 79 NA PCR NA 9.5–16.3 47 Persistent Say32 Australia PCS Clinical 3 to 6 months All severities 151 NA PCR NA 0 to 12 58 Post-acute COVID-19 Clinical 1 to 3 months Hospitalized 61 Post-acute COVID/ long-term consequences 37 Long COVID/ postCOVID symptomatology/long haulers/ post-acue COVID syndrome) Smane* 18 Stephenson33 Sterky 34 Zavala35 Latvia RCS 92 NA NR NA 8 to 15 PCS Paper questionnaire At 3 months Non-hospitalized Sweden PCS Phone questionnaire Median 7.3, range 4.1 to 10.8 months Hospitalized 55 NA PCR NA 0 to 18 58 Persistent/long COVID/ long term health issues U.K. RCS Paper questionnaire At 1 month All severities 387 472 PCR PCR nega0 to 16 tive 51 Persistent U.K. 3065 3739 PCR PCR nega11 to 17 tive Table 1.  General characteristics of studies. Controls: did not present numbers, therefore it could not be used CSS cross-sectional study, DM diabetes mellitus, NA not applicable, NR not reported, MA meta-analysis, M months, PCS prospective cohort study, RCS retrospective cohort study. *Part of the population duplicated. congestion (7.53%; 95% CI 3.78–12.36, ­I2 0%), cognitive symptoms (e.g., less concentration, learning difficulties, confusion, and memory loss) (6.27%; 95% CI 4.46–8.35, ­I2 91.32%), loss of appetite (6.07%; 95% CI 3.95–8.59, ­I2 93.54%), exercise intolerance (5.73%; 95% CI 0.00–19.38, I­ 2 87.77%), and altered smell (e.g., hyposmia, anosmia, hypersomnia, parosmia, and phantom smell) (5.60%; 95% CI 3.13–8.69, I­ 2 97.11%). All other symptoms had less than 5.00% prevalence (Table 2, Fig. 2, Supplementary Fig. 1). Meta‑analyses of O.R.s (cases vs. controls). It was only possible to perform meta-analyses of O.R.s comparing cases and controls for 13 symptoms (mood, fatigue, headache, dyspnea, concentration problems, anosmia/ageusia, loss of appetite, rhinitis, myalgia/arthralgia, cough, fever, sore throat, and nausea/vomiting) (Fig. 4). When compared to controls, children with long-COVID had a higher risk of persistent dyspnea (OR 2.69; 95% CI 2.30–3.14, ­I2 0%), anosmia/ageusia (OR 10.68; 95% CI 2.48, 46.03, I­ 2 0%), and/or fever (OR 2.23; 95% CI 1.2–4.07, ­I2 12%). There was significant heterogeneity for 4 out of the 13 meta-analyses (Fig. 4). The controls were chosen in a very different way among studies, which might have introduced significant heterogeneity. The following were the different definitions of controls, children and adolescents with: (1) other infections (e.g., common cold, pharyngotonsillitis, gastrointestinal, urinary tract infections, pneumonia of bacteria or unknown origin)17; (2) no antibodies t­ esting24 mixed with other i­nfections17; (3) a negative antibody t­ est29, (4) a negative rtPCR test among symptomatic ­children35; and (5) children who did not have a positive test recorded in the ­database15 (Supplementary Fig. 2). The adjustments among studies also varied. Several studies adjusted their OR by age, sex, ethnicity, socioeconomic status, and ­comorbidities35. However, age and s­ ex15 only adjusted for sex, only for a­ ge17, did not adjust, or by OR without adjusting previous ­conditions24. Other findings. The prevalence of symptoms over the course of long-COVID for cases and controls is shown in Supplementary Fig. 2. Given the heterogeneity in the definition of controls and the low number of subjects, no formal statistical comparison was done for the crude prevalence. The symptoms that were presented in a single study and, therefore, unable to be incorporated into the meta-analyses, include: orthostatic intolerance, cold hands/feet, chapped lips, adenopathy, fainting, twitching of fingers and toes, chills, swollen toes/fingers, and hallucinations. Scientific Reports | (2022) 12:9950 | https://doi.org/10.1038/s41598-022-13495-5 5 Vol.:(0123456789) www.nature.com/scientificreports/ Clinical manifestations Studies Cases Sample size I2 Prevalence % (95% CI) Mood (sad, tense, angry, depression, anxiety) 5 730 6047 97.49 16.50 (7.37–28.15) Fatigue 16 3015 21,592 99.12 9.66 (4.45–16.46) Sleep disorder (insomnia, hypersomnia, poor sleep quality) 8 153 1592 93.49 8.42 (3.41–15.20) Headache 13 1875 21,108 98.49 7.84 (4.04–12.70) Respiratory symptoms 9 1387 19,013 99.15 7.62 (2.08–15.78) Sputum/nasal congestion 2 11 150 0 7.53 (3.78–12.36) Cognition (less concentration, learning difficulties, confusion, memory loss) 11 1223 19,803 91.31 6.27 (4.46–8.35) Loss of appetite 5 747 9379 93.54 6.07 (3.95–8.59) Exercise intolerance 2 8 150 87.77 5.73 (0.00–19.38) Altered smell (hyposmia, anosmia, hypersomnia, parosmia, phantom 10 smell) 2048 20,818 97.11 5.60 (3.13–8.69) Hyperhidrosis 2 36 738 93.59 4.66 (0.00–13.85) Chest pain 6 467 18,777 98.24 4.62 (1.52–9.11) Dizziness 6 791 9340 97.77 4.40 (1.50–8.59) Rhinorrhea 5 65 1032 94.10 4.15 (0.10–11.89) Cough 10 570 19,688 86.60 3.80 (2.61–5.19) Myalgia/arthralgia 9 547 19,564 93.67 3.76 (2.18–5.75) Body weight changes 3 30 865 96.82 3.99 (0.00–14.00) Altered taste 5 1273 16,005 92.23 3.65 (1.35–6.92) Otalgia (tinnitus, earache, vertigo) 3 207 3773 92.65 3.41 (0.84–7.35) Ophthalmologic (conjuntivitis, dry eye, problems seeing/blurred vision, photophobia, pain) 6 384 9411 91.07 3.00 (1.66–4.69) Abdominal pain 8 277 9611 73.94 2.91 (2.04–3.92) Dermatologic (dry skin, itchy skin, rashes, hives) 6 218 9322 78.68 2.61 (1.73–3.67) Sore throat 6 401 10,311 98.46 2.47 (0.25–6.23) Chest tightness 5 293 6319 92.81 2.45 (0.58–5.35) Variations in heart rate 2 18 729 88.54 2.29 (0.00–7.36) Constipation 3 20 1101 81.01 2.05 (0.39–4.75) Dysphonia 2 62 3301 0 1.89 (1.45–2.38) Fever 5 167 18,709 96.27 1.87 (0.50–3.99) Musculoskeletal other 3 383 15,618 87.72 1.72 (0.41–3.78) Diarrhea 7 218 19,337 81.01 1.68 (0.63–3.18) Vomiting/nausea 5 260 16,144 24.91 1.53 (1.09–2.03) Changes in menstruation 3 10 866 43.98 1.27 (0.38–2.60) Palpitations 4 165 6178 93.55 1.27 (0.00–3.83) Hair loss 3 16 1209 80.31 1.17 (0.10–3.10) Neurological abnormalities (pins and needles, tremor, numbness) 3 8 997 0 0.86 (0.37–1.55) Urinary symptoms 3 6 1060 0 0.63 (0.23–1.21) Dysphagia 3 5 1207 0 0.46 (0.14–0.93) Speech disturbances 3 5 1197 40.41 0.44 (0.05–1.10) Table 2.  Pooled prevalence of symptoms in children and adolescents. One study reported statistically significant differences between clinical cases and controls for systolic blood pressure, left ventricular ejection fraction, relative myocardial wall thickness, and tricuspid annular plane systolic ­excursion22. However, given that these variables were only evaluated in this study, we could not perform a meta-analysis for these outcomes. Studies included in the meta-analyses found that certain variables, such as age, sex, severe acute-COVID-19, obesity, allergic disease, and long-term health ­conditions19,26,28,36, increased the risk of long-COVID. Further, two of the studies evaluated the duration of symptoms. A study from Denmark reported that symptoms resolved in a minimum of 54–75% of children and adolescents within 1–5 ­months16. Another from England, reported that 4.4% of children still had symptoms four weeks after COVID-19 onset, which decreased to 1.8% at 8 or more ­weeks27. Quality of studies. Regarding the quality of studies, all had a score of 7 or more (Supplementary Table 1). Table 3 presents a list of methodological strengths or limitations for each study. All studies included laboratoryconfirmed COVID-19 infection, rt-PCR, antigen, or antibody test. Two-thirds of the studies included over 100 children. Six meta-analyses had low heterogeneity (­ I2 < 25%) for the following symptoms: vomiting and nausea, nasal congestion, dysphonia, urinary problems, neurological abnormalities, and dysphagia. Three meta-analyses Scientific Reports | Vol:.(1234567890) (2022) 12:9950 | https://doi.org/10.1038/s41598-022-13495-5 6 www.nature.com/scientificreports/ Figure 2.  The pooled prevalence of long-COVID by symptoms in children and adolescents. Meta-analyses revealed that the prevalence of more than 40 long-COVID symptoms in children and adolescents. The presence of one or more symptoms following a SARS-CoV-2 infection was 25.24%. had medium heterogeneity for the following symptoms: abdominal pain, changes in menstruation, and speech disturbances. All other meta-analyses had high heterogeneity ­(I2 > 75%). Given that very few studies stratified by the different variables (e.g., age, sex, country, or past comorbidities), there were not enough studies that included this information to evaluate where the heterogeneity originated. Discussion The prevalence of long-COVID in children and adolescents was 25.24%. The five most prevalent clinical manifestations were mood symptoms (16.50%), fatigue (9.66%), sleep disorders (8.42%), headache (7.84%), and respiratory symptoms (7.62%). It was only possible to perform meta-analyses of ORs comparing cases and controls for 13 symptoms, with a higher risk of persistent dyspnea, anosmia/ageusia, and/or fever. Studies have shown that the pandemic has profoundly impacted society by affecting children’s development through isolation, poverty, food insecurity, loss of parents and caregivers, loss of time in education, and increased ­stress37. COVID-19 pandemic has initiated an explosion of future mental i­ llnesses38, affecting both society as a whole and those who recover from long-COVID. The presence of these symptoms in the general population, regardless of COVID-19 status, has been coined long-Pandemic ­Syndrome20. Scientific Reports | (2022) 12:9950 | https://doi.org/10.1038/s41598-022-13495-5 7 Vol.:(0123456789) www.nature.com/scientificreports/ Figure 3.  Forest plot of pooled prevalence of long-COVID overall in children and adolescents. Interestingly, many of the symptoms identified in these meta-analyses associated to long-COVID, such as mood, fatigue, sleep disorders, orthostatic intolerance, decreased concentration, confusion, memory loss, balance problems, exercise intolerance, hyperhidrosis, blurred vision, body temperature dysregulation, dysfunction on heart, rate variability and palpitations, constipation or diarrhea, and dysphagia, are commonly present in ­dysautonomia39. Dysautonomia is a dysfunction of the sympathetic and/or parasympathetic autonomic nervous system. However, it remains unclear whether dysautonomia may be a direct result of the SARS-CoV-2 infection, interaction with other viruses, or immune-mediated processes such as cytokines, which are known mediators of the inflammatory ­response40–43. Moreover, the constellation of symptoms because of long-COVID can vary from patient to patient, fluctuating in their frequency and ­severity44. Like adults, the pediatric population’s risk factors associated with long-COVID are older age, female gender, severe COVID-19, overweight/obesity, comorbid allergic diseases, and other longterm co-morbidities. Protective factors leading to milder severity and duration of COVID-19, and possibly also long-COVID in children, include fewer comorbidities, strong innate immune responses, reduced expression of angiotensin-converting enzyme-2 (ACE2) receptors, and active thymic function, which leads to the increased presence and decreased depletion of T cells. Further protections include a range of environmental or non-inheritable factors such as vaccines, past infections, nutrition, and/or the gut ­microbiome19,26,28,36,45. Concerning age, most of the studies did not discriminate between children (< 12-year-old) and adolescents. Given that the risk increases with age, there is a need for future studies to stratify by age. In addition, the evaluation of self-reporting symptoms can be significantly biased by age as younger children might not be able to express their emotional and functional status relevant to post-COVID-19 adequately. Further studies targeting age groups are required. The prevalence of symptoms is highly dependent on how much time has passed after having acute COVID19. The follow-up time in these meta-analyses varied between 1 and 13 months. Even though most symptoms improve with t­ ime46, there is evidence in adult studies that suggests some symptoms can persist one year after COVID-19 ­diagnosis47. It is important to understand which symptoms are associated with certain periods of time (e.g., 6 months, 12 months, 2 years). The strength of this meta-analyses focuses on the large sample s­ ize48 which helps identify the signs and symptoms present after acute SARS-CoV-2 infection. Further, there were some limitations such as the quality of the meta-analyses results depending on the quality of the studies included. Table 3 contains a list of all the methodological aspects that future studies need to consider. We can observe that all studies had a high probability of bias, including lack of standardized definitions, recall, selection, misclassification, nonresponse, and/ or loss of follow-up. Additionally, the included studies have the limitations inherited in all observational studies, including bias due to residual and unmeasured confounding, and a high level of heterogeneity. To account for heterogeneity, we used a random-effects ­model49. The differences between studies were likely due to differences in study designs, settings, populations, follow-up time, symptom ascertainment methods, inconsistent terminology, little details on stratification of pre-existing comorbidities, and prior receipt of COVID-19 therapeutics and vaccines. Only four studies mentioned what percentage of the population was already v­ accinated15,16,20,28 (Table 3). It has been shown that vaccines reduce the risk of long-COVID in a­ dults50. More studies are needed to analyze the relationship between vaccines in children with long COVID. In our analyses, we included 2 pre-publication articles that are still not peer-reviewed26,30. The limitations of the study of Roessler et al.30 are inherited from all observational studies and are mentioned above. However its strengths are that it includes a large population (n = 11,950), that physicians and psychotherapists validate the cases, and that they estimate the incidence rate ratios (IRR), controlling for age, sex, and prevalent medical conditions by applying propensity score matching. They report that symptoms were statistically higher in the acute COVID-19 cohort (IRR = 1.30) than in the controls without COVID-19. The study by Miller et al.26 included Scientific Reports | Vol:.(1234567890) (2022) 12:9950 | https://doi.org/10.1038/s41598-022-13495-5 8 www.nature.com/scientificreports/ Figure 4.  Pooled odds ratios with 95% CI in cases vs. controls. The size of each box indicates the effect of each study by symptom assigned using the odds ratios (95% CI) by age and domain. children participating in VirusWatch, a household cohort in England and Wales that recruited households via postcards, social media, and SMS that had as an objective to study acute COVID-19. Long-COVID was defined as answering “YES” to the following question—“Have you presented any new symptoms that have lasted for four or more weeks even if these symptoms come and go and cannot be explained by something else?”. Given the nature of the survey, it has a possibility of introducing bias to the results (recall bias, selection bias, misclassification bias, and nonresponse bias). The study does not present the frequencies for each symptom, and therefore it was not Scientific Reports | (2022) 12:9950 | https://doi.org/10.1038/s41598-022-13495-5 9 Vol.:(0123456789) www.nature.com/scientificreports/ No of studies (N = 21) Prevalence (%) COVID cases lab confirmed (PCR or antibody) 21 100 More than 100 COVID patients 14 66.66 Timing of COVID well specified 14 66.66 Long COVID defined > 3 months 8 38.10 Point in time specific and well defined 10 42.11 Control added 8 31.60 Study methodological strength Control group with negative antibody test 2 10.50 Clinical assessment (not self/parent reported) 7 36.84 New symptoms on or after COVID 6 31.58 Specify if persistent symptom or if it is symptoms months after acute COVID 2 9.52 Exclude vaccinated/no vaccinated in sample 4 19.05 Duration (end) of symptoms specified 3 14.29 Validated questionnaires or clinical evaluation for symptoms 5 23.81 Bias Low chance of recall bias 7 33.33 Low chance of selection bias 4 19.05 Low chance of misclassification bias 3 14.29 Low chance of nonresponse bias/loss of follow up 3 14.29 Stratifications Stratify by severity/only one severity 4 19.05 Stratified by age/only one age group studied 6 28.57 Stratified by preexisting medical conditions 1 4.76 Stratified by sex 2 9.52 Stratify by vaccination status 0 0 Table 3.  Study methodological strengths and limitations. included in the meta-analyses of each symptom. We only included this study in the meta-analysis of overall longCOVID. The authors estimated a prevalence of 4.6%, which, compared to the other studies, is underestimated. Future prospective studies should include a control cohort and stratify and/or adjust their results by age, sex, race, severity of acute COVID-19 infection paired with clinical evaluation, vaccination status, preexisting medical conditions, and, if possible, SARS-CoV-2 variant. Retrospective studies using large population-based databases with historical controls and secondary data sources (e.g., claims and medical records) should also be used. The selection of controls will be difficult in the future because not all the cases are recorded in databases (e.g., home tests), tests can be false, negative, or positive, or children can be asymptomatic. Future studies’ proposed control groups include a negative N protein antibody test without vaccination, a negative antibody test with vaccination, or historical cohorts that include children who have neither been vaccinated nor exposed to the virus. Conclusion Protective measures are essential to prevent long-COVID in children. We need to understand the long-COVID pathophysiology and symptomatology to support clinical management systems, establish rehabilitation programs, and design guidelines and therapeutic research. Long-COVID represents a significant public health concern, and there are no guidelines to address its diagnosis and management. Our meta-analyses further support the importance of continuously monitoring the impact of long-COVID in children and adolescents and the need to include all variables and appropriate control cohorts in studies to better understand the real burden of pediatric long-COVID. Data availability All data relevant to the study are included in the article or uploaded as Supplementary Information. In addition, the datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request. Received: 12 March 2022; Accepted: 25 May 2022 References 1. Cucinotta, D. & Vanelli, M. WHO declares COVID-19 a pandemic. Acta Biomed. 91, 157–160. https://​doi.​org/​10.​23750/​abm.​ v91i1.​9397 (2020). 2. Agarwal, A. et al. A living WHO guideline on drugs for covid-19. BMJ 370, m3379. https://​doi.​org/​10.​1136/​bmj.​m3379 (2020). Scientific Reports | Vol:.(1234567890) (2022) 12:9950 | https://doi.org/10.1038/s41598-022-13495-5 10 www.nature.com/scientificreports/ 3. Chua, P. E. Y. et al. Epidemiological and clinical characteristics of non-severe and severe pediatric and adult COVID-19 patients across different geographical regions in the early phase of pandemic: A systematic review and meta-analysis of observational studies. J. Investig. Med. 69, 1287–1296. https://​doi.​org/​10.​1136/​jim-​2021-​001858 (2021). 4. Kundu, A. et al. Clinical aspects and presumed etiology of multisystem inflammatory syndrome in children (MIS-C): A review. Clin. Epidemiol. Glob. Health 14, 100966. https://​doi.​org/​10.​1016/j.​cegh.​2022.​100966 (2022). 5. Helms, J. et al. Neurologic features in severe SARS-CoV-2 infection. N. Engl. J. Med. 382, 2268–2270. https://​doi.​org/​10.​1056/​ NEJMc​20085​97 (2020). 6. Soriano, J. B. et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. https://​doi.​ org/​10.​1016/​S1473-​3099(21)​00703-9 (2021). 7. Clements, W., Joseph, T. & Koukounaras, J. UK NICE guidelines for EVAR: Cost implications for post-COVID Australian Public Health. Cardiovasc Intervent. Radiol. 44, 1286–1288. https://​doi.​org/​10.​1007/​s00270-​021-​02832-2 (2021). 8. Nalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. 27, 601–615. https://d ​ oi.o ​ rg/1​ 0.1​ 038/s​ 41591-0​ 21-0​ 1283-z (2021). 9. Behnood, S. A. et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: A meta-analysis of controlled and uncontrolled studies. J. Infect. 84, 158–170. https://​doi.​org/​10.​1016/j.​jinf.​2021.​11.​011 (2022). 10. Lopez-Leon, S. et al. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 11, 16144. https://​doi.​org/​10.​1038/​s41598-​021-​95565-8 (2021). 11. Bialek, S. et al. Coronavirus disease 2019 in Children—United States, February 12-April 2, 2020. Morb. Mortal Wkly. Rep. 69, 422–426. https://​doi.​org/​10.​15585/​mmwr.​mm691​4e4 (2020). 12. Page, M. J. et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. Rev. Esp. Cardiol. (Engl. Ed.) 74, 790–799. https://​doi.​org/​10.​1016/j.​rec.​2021.​07.​010 (2021). 13. Barendregt, J. J., Doi, S. A., Lee, Y. Y., Norman, R. E. & Vos, T. Meta-analysis of prevalence. J. Epidemiol. Community Health 67, 974–978. https://​doi.​org/​10.​1136/​jech-​2013-​203104 (2013). 14. DerSimonian, R. & Laird, N. Meta-analysis in clinical trials revisited. Contemp. Clin. Trials 45, 139–145. https://​doi.​org/​10.​1016/j.​ cct.​2015.​09.​002 (2015). 15. Kikkenborg Berg, S. et al. Long COVID symptoms in SARS-CoV-2-positive adolescents and matched controls (LongCOVIDKidsDK): A national, cross-sectional study. Lancet Child Adolesc. Health. https://​doi.​org/​10.​1016/​S2352-​4642(22)​00004-9 (2022). 16. Borch, L., Holm, M., Knudsen, M., Ellermann-Eriksen, S. & Hagstroem, S. Long COVID symptoms and duration in SARS-CoV-2 positive children—A nationwide cohort study. Eur. J. Pediatr. https://​doi.​org/​10.​1007/​s00431-​021-​04345-z (2022). 17. Roge, I. et al. Comparison of persistent symptoms after COVID-19 and other non-SARS-CoV-2 infections in children. Front. Pediatr. 9, 752385. https://​doi.​org/​10.​3389/​fped.​2021.​752385 (2021). 18. Smane, L., Roge, I., Pucuka, Z. & Pavare, J. Clinical features of pediatric post-acute COVID-19: A descriptive retrospective followup study. Ital. J. Pediatr. 47, 177. https://​doi.​org/​10.​1186/​s13052-​021-​01127-z (2021). 19. Asadi-Pooya, A. A. et al. Long COVID in children and adolescents. World J. Pediatr. 17, 495–499. https://​doi.​org/​10.​1007/​s12519-​ 021-​00457-6 (2021). 20. Blankenburg, J. et al. Comparison of mental health outcomes in seropositive and seronegative adolescents during the COVID19 pandemic. Sci. Rep. 12, 2246. https://​doi.​org/​10.​1038/​s41598-​022-​06166-y (2022). 21. Buonsenso, D. et al. Preliminary evidence on long COVID in children. Acta Paediatr. 110, 2208–2211. https://​doi.​org/​10.​1111/​ apa.​15870 (2021). 22. Erol, N., Alpinar, A., Erol, C., Sari, E. & Alkan, K. Intriguing new faces of Covid-19: Persisting clinical symptoms and cardiac effects in children. Cardiol. Young. https://​doi.​org/​10.​1017/​S1047​95112​10036​93 (2021). 23. Fink, T. T. et al. Persistent symptoms and decreased health-related quality of life after symptomatic pediatric COVID-19: A prospective study in a Latin American tertiary hospital. Clinics (Sao Paulo) 76, e3511. https://​doi.​org/​10.​6061/​clini​cs/​2021/​e3511 (2021). 24. Knoke, L. S. A., Maier, C., Eitner, L., Lücke, T. & Brinkmann, F. Pulmonary function and long-term respiratory symptoms in children and adolescents after COVID-19. Front. Pediatr. https://​doi.​org/​10.​3389/​fped.​2022.​851008 (2022). 25. Matteudi, T. et al. Clinical characteristics of paediatric COVID-19 patients followed for up to 13 months. Acta Paediatr. 110, 3331–3333. https://​doi.​org/​10.​1111/​apa.​16071 (2021). 26. Miller, F. N. V. et al. Prevalence of persistent symptoms in children during the COVID-19 pandemic: Evidence from a household cohort study in England and Wales. MedRxiv. https://​doi.​org/​10.​1101/​2021.​05.​28.​21257​602 (2021). 27. Molteni, E. et al. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2. Lancet Child Adolesc. Health 5, 708–718. https://​doi.​org/​10.​1016/​S2352-​4642(21)​00198-X (2021). 28. Osmanov, I. M. et al. Risk factors for post-COVID-19 condition in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study. Eur. Respir. J. 59, 2101341. https://​doi.​org/​10.​1183/​13993​003.​01341-​2021 (2022). 29. Radtke, T., Ulyte, A., Puhan, M. A. & Kriemler, S. Long-term symptoms after SARS-CoV-2 infection in children and adolescents. JAMA https://​doi.​org/​10.​1001/​jama.​2021.​11880 (2021). 30. Roessler, M. T. F. et al. Post COVID-19 in children, adolescents, and adults: Results of a matched cohort study including more than 150,000 individuals with COVID-19. MedRxiv 6, 100122 (2021). 31. Rusetsky, Y. et al. Smell status in children infected with SARS-CoV-2. Laryngoscope 131, E2475–E2480. https://​doi.​org/​10.​1002/​ lary.​29403 (2021). 32. Say, D. et al. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. Lancet Child Adolesc. Health 5, e22–e23. https://​doi.​org/​10.​1016/​S2352-​4642(21)​00124-3 (2021). 33. Stephenson, T. et al. Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): A national matched cohort study. Lancet Child Adolesc. Health 6, 230–239. https://​doi.​org/​10.​1016/​S2352-​4642(22)​ 00022-0 (2022). 34. Sterky, E. et al. Persistent symptoms in Swedish children after hospitalisation due to COVID-19. Acta Paediatr. 110, 2578–2580. https://​doi.​org/​10.​1111/​apa.​15999 (2021). 35. Zavala, M., Ireland, G., Amin-Chowdhury, Z., Ramsay, M. E. & Ladhani, S. N. Acute and persistent symptoms in children with PCR-confirmed SARS-CoV-2 infection compared to test-negative children in England: Active, prospective, national surveillance. Clin. Infect. Dis. https://​doi.​org/​10.​1093/​cid/​ciab9​91 (2021). 36. Molteni, E. et al. Long COVID in children—Authors’ reply. Lancet Child Adolesc. Health 6, e3. https://​doi.​org/​10.​1016/​S2352-​ 4642(21)​00344-8 (2022). 37. Ravens-Sieberer, U. et al. Mental health and psychological burden of children and adolescents during the first wave of the COVID19 pandemic-results of the COPSY study. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 64, 1512–1521. https://​ doi.​org/​10.​1007/​s00103-​021-​03291-3 (2021). 38. Solmi, M. et al. Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during infection times—Children and Adolescents (COH-FIT-C&A). J. Affect. Disord. 299, 367–376. https://​doi.​org/​10.​1016/j.​jad.​2021.​09.​090 (2022). 39. Dotan, A., David, P., Arnheim, D. & Shoenfeld, Y. The autonomic aspects of the post-COVID19 syndrome. Autoimmun. Rev. 21, 103071. https://​doi.​org/​10.​1016/j.​autrev.​2022.​103071 (2022). 40. Evans, S. S., Repasky, E. A. & Fisher, D. T. Fever and the thermal regulation of immunity: The immune system feels the heat. Nat. Rev. Immunol. 15, 335–349. https://​doi.​org/​10.​1038/​nri38​43 (2015). 41. Atzeni, F. et al. One year in review 2019: Fibromyalgia. Clin. Exp. Rheumatol. 37(Suppl 116), 3–10 (2019). Scientific Reports | (2022) 12:9950 | https://doi.org/10.1038/s41598-022-13495-5 11 Vol.:(0123456789) www.nature.com/scientificreports/ 42. Caronna, E. & Pozo-Rosich, P. Headache during COVID-19: Lessons for all, implications for the International Classification of Headache Disorders. Headache 61, 385–386. https://​doi.​org/​10.​1111/​head.​14059 (2021). 43. Barizien, N. et al. Clinical characterization of dysautonomia in long COVID-19 patients. Sci. Rep. 11, 14042. https://​doi.​org/​10.​ 1038/​s41598-​021-​93546-5 (2021). 44. Sharif, K. et al. On chronic fatigue syndrome and nosological categories. Clin. Rheumatol. 37, 1161–1170. https://​doi.​org/​10.​1007/​ s10067-​018-​4009-2 (2018). 45. Brodin, P. et al. Variation in the human immune system is largely driven by non-heritable influences. Cell 160, 37–47. https://​doi.​ org/​10.​1016/j.​cell.​2014.​12.​020 (2015). 46. Seessle, J. et al. Persistent symptoms in adult patients one year after COVID-19: A prospective cohort study. Clin. Infect. Dis. https://​ doi.​org/​10.​1093/​cid/​ciab6​11 (2021). 47. Fumagalli, C. et al. Factors associated with persistence of symptoms 1 year after COVID-19: A longitudinal, prospective phonebased interview follow-up cohort study. Eur. J. Intern. Med. https://​doi.​org/​10.​1016/j.​ejim.​2021.​11.​018 (2021). 48. Finckh, A. & Tramer, M. R. Primer: Strengths and weaknesses of meta-analysis. Nat. Clin. Pract. Rheumatol. 4, 146–152. https://​ doi.​org/​10.​1038/​ncprh​eum07​32 (2008). 49. Cumpston, M. et al. Updated guidance for trusted systematic reviews: A new edition of the cochrane handbook for systematic reviews of interventions. Cochrane Database Syst. Rev. 10, ED000142. https://​doi.​org/​10.​1002/​14651​858.​ED000​142 (2019). 50. Kuodi, P. G. Y. et al. Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: A cross-sectional study of patients tested between March 2020 and November 2021. MedRxiv. https://​doi.​org/​10.​1101/​2022.​01.​ 05.​22268​800 (2022).